PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1290845
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1290845
Next-Generation Antibody Therapeutics Market with COVID-19 Impact Analysis, By Therapeutic Area, By Technology, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
REPORT HIGHLIGHT
Next-Generation Antibody Therapeutics Market size was valued at USD 5,007.1 million in 2022, expanding at a CAGR of 10.3% from 2023 to 2030.
The next generation of antibody therapeutics, with engineering to enhance characteristics such as target cell-killing potency. These include antibody-drug conjugates (ADCs), bispecific antibodies, engineered antibodies, antibody fragments, and Nanobodies. Monoclonal antibodies (mAb) are emerging as one of the major class of therapeutic agents in the treatment of many human diseases, in particular in cancer and immunological disorders. To date, 28 mAb have been approved by the United States Food and Drug Administration for clinical applications. In addition, several hundreds of mAb are being developed clinically by many biotech and pharmaceutical companies for various disease indications.
Next-Generation Antibody Therapeutics Market- Market Dynamics
Increase in the prevalence of different chronic diseases such as rheumatoid arthritis, inflammatory bowel disorder, Crohn's disease, and cancer to propel market demand
Next-generation antibody therapeutics hold significant promise in the treatment of chronic diseases. Several chronic diseases have seen a rise in their prevalence in recent years, including cardiovascular diseases, diabetes, cancer, autoimmune disorders, neurodegenerative diseases, and respiratory conditions, among others. According to the world health organization, Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. However, Traditional treatment options for chronic diseases include chemotherapy, radiation, immunosuppressive drugs, and long-term use of medications to control symptoms. with continued advancements in the field of biotechnology and the growing understanding of disease mechanisms, next-generation antibody therapeutics have the potential to revolutionize the treatment landscape for various chronic diseases, improving patient results and quality of life.
Next-Generation Antibody Therapeutics Market- Key Insights
- As per the analysis shared by our research analyst, the global Next-Generation Antibody Therapeutics market is estimated to grow annually at a CAGR of around XX% over the forecast period (2023-2030)
- The Next-Generation Antibody Therapeutics industry is projected to grow at a significant rate due to the growing awareness of sustainable growth
- Based on therapeutic area segmentation, Oncology was predicted to show maximum market share in the year 2022
- Based on technology segmentation, Antibody-Drug Conjugates were the leading type in 2022
- On the basis of region, North America was the leading revenue generator in 2022
Next-Generation Antibody Therapeutics Market- Segmentation Analysis:
The Global Next-Generation Antibody Therapeutics Market is segmented on the basis of therapeutic area, Technology, and Region.
The market is divided into three categories based on Therapeutic areas: Oncology and Autoimmune/Inflammatory. Oncology dominates the market and is likely to maintain its dominance during the forecast period. Oncology is one of the key therapeutic areas where next-generation antibody therapeutics have made significant advancements and demonstrated great potential.
The market is divided into three categories based on technology: Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, Fc-engineered Antibodies, Antibody Fragments and Antibody-like Proteins, and Biosimilar Antibody Products. Antibody-Drug Conjugates dominates Next-Generation Antibody Therapeutics Market. Antibody-drug conjugates (ADCs) are a class of next-generation antibody therapeutics that combine the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs.
Next-Generation Antibody Therapeutics Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is anticipated to dominate the growth of the next-generation antibody therapeutics market, due to the rise in auto-immune diseases, and increased healthcare expenditure. Next-generation antibody therapeutics show significant promise in the treatment of autoimmune diseases by offering targeted and specific interventions. According to the National Institutes of Health, up to 23.5 million Americans suffer from an autoimmune disease and the prevalence is rising. next-generation antibody therapeutics have the potential to address some of these challenges and potentially contribute to more efficient healthcare spending. In 2021, spending was USD187.6 billion, less than the unprecedented levels in 2020, but still higher than before the pandemic. Government-sponsored pandemic relief resulted in other federal programs spending increasing from only USD14.0 billion in 2019 to USD193.1 billion in 2020. In 2021, spending was USD71.9 billion, according to American Medical Association. Overall, Next-Generation Antibody Therapeutics Market is expected to experience significant growth opportunities in all regions.
Next-Generation Antibody Therapeutics Market- Competitive Landscape:
An assembly of novel therapeutic antibody formats based on the modification of the conventional IgG format has arisen in recent years. In addition, several hundreds of Next-Generation Antibody Therapeutics are being developed clinically by many biotech and pharmaceutical companies for various disease indications. Many challenges still remain, however, and the full potential of therapeutic antibodies has yet to be realized. With the advancement of antibody engineering technologies and further understanding of disease biology as well as antibody mechanism of action, many classes of novel antibody formats or antibody-derived molecules are emerging as promising new-generation therapeutics. These new antibody formats or molecules are carefully designed and engineered to acquire special features, such as improved pharmacokinetics, increased selectivity, and enhanced efficacy. Numerous companies and research institutions are actively involved in the development and commercialization of these innovative therapies. For instance, on Jan. 6, 2022, Amgen and Generate Biomedicines nowadays announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.
Recent Developments:
In September 2022, the Evolution of monoclonal antibodies resulted in the next generation of antibody therapeutics, with engineering to enhance characteristics such as target cell-killing potency. These include antibody-drug conjugates (ADCs), bispecific antibodies, engineered antibodies, antibody fragments, and Nano bodies.
Key features of the study:
- This proposed research study on Next-Generation Antibody Therapeutics market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
- The report provides the client the latest up-to-date and trending insights about the Next-Generation Antibody Therapeutics market.
- The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for the Next-Generation Antibody Therapeutics market
- The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Next-Generation Antibody Therapeutics market
- Impact of COVID-19 on Next-Generation Antibody Therapeutics market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Next-Generation Antibody Therapeutics market post-COVID will also be covered.
- In order to give the users of this report a comprehensive view on the Next-Generation Antibody Therapeutics market, we have also included competitive landscape and key innovator analysis for the Next-Generation Antibody Therapeutics market.
- The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
- The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Next-Generation Antibody Therapeutics market.
- In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
- The global Next-Generation Antibody Therapeutics market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET KEY PLAYERS
- Pfizer
- Roche
- Bristol-Myers Squibb
- Amgen
- AstraZeneca
- Bayer
- Takeda Pharmaceuticals
- Biogen
- Seattle Genetics
- ImmunoGen
- Kyowa Hakko Kirin
- Xencor
- Dyax CorpC
GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY THERAPEUTIC AREA
- Oncology
- Autoimmune/Inflammatory
GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY TECHNOLOGY
- Antibody-Drug Conjugates (ADCs)
- Bispecific Antibodies
- Fc-engineered Antibodies
- Antibody Fragments and Antibody-like Proteins
- Biosimilar Antibody Products
GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Next-Generation Antibody Therapeutics Market Overview
- 1.1. Study Scope
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Next-Generation Antibody Therapeutics Market Snippet by Therapeutic Area
- 2.1.2. Next-Generation Antibody Therapeutics Market Snippet by Technology
- 2.1.3. Next-Generation Antibody Therapeutics Market Snippet by Country
- 2.1.4. Next-Generation Antibody Therapeutics Market Snippet by Region
- 2.2. Competitive Insights
3. Next-Generation Antibody Therapeutics Key Market Trends
- 3.1. Next-Generation Antibody Therapeutics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Next-Generation Antibody Therapeutics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Next-Generation Antibody Therapeutics Market Opportunities
- 3.4. Next-Generation Antibody Therapeutics Market Future Trends
4. Next-Generation Antibody Therapeutics Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Next-Generation Antibody Therapeutics Market: COVID-19 Impact Analysis
- 5.1. Pre-COVID-19 Impact Analysis
- 5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments
6. Next-Generation Antibody Therapeutics Market Landscape
- 6.1. Next-Generation Antibody Therapeutics Market Share Analysis, 2022
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Next-Generation Antibody Therapeutics Market - By Therapeutic Area
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Therapeutic Area, 2022 & 2030 (%)
- 7.1.2. Oncology
- 7.1.3. Autoimmune/Inflammatory
8. Next-Generation Antibody Therapeutics Market - By Technology
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Technology, 2022 & 2030 (%)
- 8.1.2. Antibody-Drug Conjugates (ADCs)
- 8.1.3. Bispecific Antibodies
- 8.1.4. Fc-engineered Antibodies
- 8.1.5. Antibody Fragments and Antibody-like Proteins
- 8.1.6. Biosimilar Antibody Products
9. Next-Generation Antibody Therapeutics Market- By Geography
- 9.1. Introduction
- 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
- 9.2. North America
- 9.2.1. Overview
- 9.2.2. Next-Generation Antibody Therapeutics Key Manufacturers in North America
- 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.2.4. North America Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.2.5. North America Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.2.6. U.S.
- 9.2.6.1. Overview
- 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.2.6.3. U.S. Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.2.6.4. U.S. Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.2.7. Canada
- 9.2.7.1. Overview
- 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.2.7.3. Canada Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.2.7.4. Canada Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3. Europe
- 9.3.1. Overview
- 9.3.2. Next-Generation Antibody Therapeutics Key Manufacturers in Europe
- 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.3.4. Europe Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.5. Europe Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.6. Germany
- 9.3.6.1. Overview
- 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.6.3. Germany Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.6.4. Germany Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.7. Italy
- 9.3.7.1. Overview
- 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.7.3. Italy Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.7.4. Italy Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.8. United Kingdom
- 9.3.8.1. Overview
- 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.8.3. United Kingdom Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.8.4. United Kingdom Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.9. France
- 9.3.9.1. Overview
- 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.9.3. France Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.9.4. France Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.10. Russia
- 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.10.2. Russia Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.10.3. Russia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.11. Netherlands
- 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.11.2. Netherlands Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.11.3. Netherlands Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.12. Sweden
- 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.12.2. Sweden Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.12.3. Sweden Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.13. Poland
- 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.13.2. Poland Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.13.3. Poland Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.3.14. Rest of Europe
- 9.3.14.1. Overview
- 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.3.14.3. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.3.14.4. Rest of the Europe Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4. Asia Pacific (APAC)
- 9.4.1. Overview
- 9.4.2. Next-Generation Antibody Therapeutics Key Manufacturers in Asia Pacific
- 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.4.4. Asia Pacific Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.5. Asia Pacific Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.6. India
- 9.4.6.1. Overview
- 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.6.3. India Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.6.4. India Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.7. China
- 9.4.7.1. Overview
- 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.7.3. China Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.7.4. China Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.8. Japan
- 9.4.8.1. Overview
- 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.8.3. Japan Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.8.4. Japan Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.9. South Korea
- 9.4.9.1. Overview
- 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.9.3. South Korea Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.9.4. South Korea Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.10. Australia
- 9.4.10.1. Overview
- 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.10.3. Australia Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.10.4. Australia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.11. Thailand
- 9.4.11.1. Overview
- 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.11.3. Thailand Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.11.4. Thailand Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.12. Indonesia
- 9.4.12.1. Overview
- 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.12.3. Indonesia Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.12.4. Indonesia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.13. Philippines
- 9.4.13.1. Overview
- 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.13.3. Philippines Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.13.4. Philippines Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.4.14. Rest of APAC
- 9.4.14.1. Overview
- 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.4.14.3. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.4.14.4. Rest of APAC Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.5. Latin America
- 9.5.1. Overview
- 9.5.2. Next-Generation Antibody Therapeutics Key Manufacturers in Latin America
- 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.5.4. Latin America Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.5.5. Latin America Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.5.6. Brazil
- 9.5.6.1. Overview
- 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.5.6.3. Brazil Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.5.6.4. Brazil Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.5.7. Mexico
- 9.5.7.1. Overview
- 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.5.7.3. Mexico Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.5.7.4. Mexico Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.5.8. Argentina
- 9.5.8.1. Overview
- 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.5.8.3. Argentina Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.5.8.4. Argentina Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.5.9. Colombia
- 9.5.9.1. Overview
- 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.5.9.3. Colombia Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.5.9.4. Colombia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.5.10. Rest of LATAM
- 9.5.10.1. Overview
- 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.5.10.3. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.5.10.4. Rest of LATAM Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.6. Middle East and Africa
- 9.6.1. Overview
- 9.6.2. Next-Generation Antibody Therapeutics Key Manufacturers in Middle East and Africa
- 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
- 9.6.4. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.6.5. Middle East and Africa Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.6.6. Saudi Arabia
- 9.6.6.1. Overview
- 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.6.3. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.6.6.4. Saudi Arabia Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.6.7. United Arab Emirates
- 9.6.7.1. Overview
- 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.7.3. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.6.7.4. United Arab Emirates Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.6.8. Israel
- 9.6.8.1. Overview
- 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.8.3. Israel Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.6.8.4. Israel Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.6.9. Turkey
- 9.6.9.1. Overview
- 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.9.3. Turkey Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.6.9.4. Turkey Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.6.10. Algeria
- 9.6.10.1. Overview
- 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.10.3. Algeria Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.6.10.4. Algeria Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.6.11. Egypt
- 9.6.11.1. Overview
- 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.11.3. Egypt Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.6.11.4. Egypt Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
- 9.6.12. Rest of MEA
- 9.6.12.1. Overview
- 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
- 9.6.12.3. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2018 - 2030 (US$ Million)
- 9.6.12.4. Rest of MEA Market Size and Forecast, By Technology, 2018 - 2030 (US$ Million)
10. Key Vendor Analysis- Next-Generation Antibody Therapeutics Industry
- 10.1. Competitive Dashboard
- 10.2. Company Profiles
- 10.2.1. Pfizer
- 10.2.2. Roche
- 10.2.3. Bristol-Myers Squibb
- 10.2.4. Amgen
- 10.2.5. AstraZeneca
- 10.2.6. Bayer
- 10.2.7. Takeda Pharmaceuticals
- 10.2.8. Biogen
- 10.2.9. Seattle Genetics
- 10.2.10. ImmunoGen
- 10.2.11. Kyowa Hakko Kirin
- 10.2.12. Xencor
- 10.2.13. Dyax CorpC
11. 360 Degree Analyst View
12. Appendix
- 12.1. Research Methodology
- 12.2. References
- 12.3. Abbreviations
- 12.4. Disclaimer
- 12.5. Contact Us
List of Tables
- TABLE List of data sources
- TABLE Market drivers; Impact Analysis
- TABLE Market restraints; Impact Analysis
- TABLE Next-Generation Antibody Therapeutics Market: Therapeutic Area Snapshot (2022)
- TABLE Segment Dashboard; Definition and Scope, by Therapeutic Area
- TABLE Global Next-Generation Antibody Therapeutics Market, by Therapeutic Area 2018-2030 (USD Million)
- TABLE Next-Generation Antibody Therapeutics Market: Technology Snapshot (2022)
- TABLE Segment Dashboard; Definition and Scope, by Technology
- TABLE Global Next-Generation Antibody Therapeutics Market, by Technology 2018-2030 (USD Million)
- TABLE Next-Generation Antibody Therapeutics Market: Regional snapshot (2022)
- TABLE Segment Dashboard; Definition and Scope, by Region
- TABLE Global Next-Generation Antibody Therapeutics Market, by Region 2018-2030 (USD Million)
- TABLE North America Next-Generation Antibody Therapeutics Market, by Country, 2018-2030 (USD Million)
- TABLE North America Next-Generation Antibody Therapeutics Market, by Therapeutic Area, 2018-2030 (USD Million)
- TABLE North America Next-Generation Antibody Therapeutics Market, by Technology, 2018-2030 (USD Million)
- TABLE Europe Next-Generation Antibody Therapeutics Market, by Country, 2018-2030 (USD Million)
- TABLE Europe Next-Generation Antibody Therapeutics Market, by Therapeutic Area, 2018-2030 (USD Million)
- TABLE Europe Next-Generation Antibody Therapeutics Market, by Technology, 2018-2030 (USD Million)
- TABLE Asia Pacific Next-Generation Antibody Therapeutics Market, by Country, 2018-2030 (USD Million)
- TABLE Asia Pacific Next-Generation Antibody Therapeutics Market, by Therapeutic Area, 2018-2030 (USD Million)
- TABLE Asia Pacific Next-Generation Antibody Therapeutics Market, by Technology, 2018-2030 (USD Million)
- TABLE Latin America Next-Generation Antibody Therapeutics Market, by Country, 2018-2030 (USD Million)
- TABLE Latin America Next-Generation Antibody Therapeutics Market, by Therapeutic Area, 2018-2030 (USD Million)
- TABLE Latin America Next-Generation Antibody Therapeutics Market, by Technology, 2018-2030 (USD Million)
- TABLE Middle East and Africa Next-Generation Antibody Therapeutics Market, by Country, 2018-2030 (USD Million)
- TABLE Middle East and Africa Next-Generation Antibody Therapeutics Market, by Therapeutic Area, 2018-2030 (USD Million)
- TABLE Middle East and Africa Next-Generation Antibody Therapeutics Market, by Technology, 2018-2030 (USD Million)
